153 related articles for article (PubMed ID: 36598731)
1. Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
Nishihara D; Kijima T; Arai K; Kamai T
Int Urol Nephrol; 2023 Apr; 55(4):867-874. PubMed ID: 36598731
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
[TBL] [Abstract][Full Text] [Related]
3. Histological variants and lymphovascular invasion in upper tract urothelial carcinoma can stratify prognosis after radical nephroureterectomy.
Takemoto K; Hayashi T; Hsi RS; Kobatake K; Sekino Y; Kitano H; Ikeda K; Goto K; Hieda K; Sentani K; Kajiwara M; Nishizaka T; Teishima J; Oue N; Hinata N
Urol Oncol; 2022 Dec; 40(12):539.e9-539.e16. PubMed ID: 36244916
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma.
Mizuno T; Kamai T; Tsuzuki T; Nishihara D; Kijima T; Arai K; Yoshida KI
Cancer Immunol Immunother; 2022 Mar; 71(3):565-578. PubMed ID: 34275008
[TBL] [Abstract][Full Text] [Related]
5. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
[TBL] [Abstract][Full Text] [Related]
6. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
7. Association between lymphovascular invasion and oncological outcome in node-negative upper tract urothelial carcinoma with different stage.
Chen CS; Lin CY; Wang CL; Wang SS; Li JR; Yang CK; Cheng CL; Chiu KY; Yang SF
Urol Oncol; 2021 Feb; 39(2):132.e13-132.e26. PubMed ID: 32900630
[TBL] [Abstract][Full Text] [Related]
8. Prognostic indicators for upper tract urothelial carcinoma after radical nephroureterectomy: the impact of lymphovascular invasion.
Godfrey MS; Badalato GM; Hruby GW; Razmjoo M; McKiernan JM
BJU Int; 2012 Sep; 110(6):798-803. PubMed ID: 22313599
[TBL] [Abstract][Full Text] [Related]
9. Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study.
Yamada Y; Nakagawa T; Miyakawa J; Kawai T; Taguchi S; Tabata M; Kaneko T; Ishikawa A; Miyazaki H; Kondo Y; Matsumoto A; Naito A; Hikatsu M; Fujii Y; Akiyama Y; Yamada Y; Sato Y; Nomiya A; Yamada D; Murata T; Suzuki M; Enomoto Y; Nishimatsu H; Takeuchi T; Tanaka Y; Kume H
World J Urol; 2023 Mar; 41(3):767-776. PubMed ID: 36739339
[TBL] [Abstract][Full Text] [Related]
10. Expression of GLUT4 and FAP in urothelial bladder carcinoma: correlation with angiogenesis and clinicopathological characteristics.
Abd El-Azeem MA; Ali MA; El-Shorbagy SH
J Egypt Natl Canc Inst; 2022 Sep; 34(1):40. PubMed ID: 36155866
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
[TBL] [Abstract][Full Text] [Related]
12. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
[TBL] [Abstract][Full Text] [Related]
14. PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy.
Yeh HC; Margulis V; Singla N; Hernandez E; Panwar V; Woldu SL; Karam JA; Wood CG; Weizer AZ; Raman JD; Remzi M; Rioux-Leclercq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Li CC; Ke HL; Li WM; Lee HY; Rapoport LM; Lotan Y; Kapur P; Shariat SF; Hsieh JT; Wu WJ
Urol Oncol; 2020 May; 38(5):496-505. PubMed ID: 31862213
[TBL] [Abstract][Full Text] [Related]
15. HHLA2 immune-regulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
[TBL] [Abstract][Full Text] [Related]
16. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
[TBL] [Abstract][Full Text] [Related]
17. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
Zhang X; Qin Y; Chen X; Xiong M; Shu S
Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
[No Abstract] [Full Text] [Related]
18. Prognostic values of B7-H3, B7-H4, and HHLA2 expression in human pancreatic cancer tissues based on mIHC and spatial distribution analysis.
Zhu Y; Chen J; Liu Y; Zheng X; Feng J; Chen X; Jiang T; Li Y; Chen L
Pathol Res Pract; 2022 Jun; 234():153911. PubMed ID: 35489125
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of stromal periostin expression in upper urinary tract urothelial carcinoma.
Miyai K; Kawamura K; Ito K; Matsukuma S; Tsuda H
BMC Cancer; 2022 Jul; 22(1):787. PubMed ID: 35850759
[TBL] [Abstract][Full Text] [Related]
20. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
